These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23886170)

  • 21. Receptor discordances after neoadjuvant chemotherapy and their effects on survival.
    Tural D; Karaca M; Zirtiloglu A; M Hacioglu B; Sendur MA; Ozet A
    J BUON; 2019; 24(1):20-25. PubMed ID: 30941947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Veronesi P; Torrisi R; Montagna E; Luini A; Intra M; Gentilini O; Ghisini R; Goldhirsch A; Colleoni M
    Ann Oncol; 2010 Oct; 21(10):1974-1981. PubMed ID: 20332136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
    Liedtke C; Mazouni C; Hess KR; André F; Tordai A; Mejia JA; Symmans WF; Gonzalez-Angulo AM; Hennessy B; Green M; Cristofanilli M; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2008 Mar; 26(8):1275-81. PubMed ID: 18250347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
    Zhang J; Wang Z; Hu X; Wang B; Wang L; Yang W; Liu Y; Liu G; Di G; Hu Z; Wu J; Shao Z
    Int J Cancer; 2015 Jan; 136(1):204-11. PubMed ID: 24824628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
    Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors and survival outcome in cerebral metastatic breast cancer.
    Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
    Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
    Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
    Halim A; Wahba H
    Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
    Joensuu H; Sailas L; Alanko T; Sunela K; Huuhtanen R; Utriainen M; Kokko R; Bono P; Wigren T; Pyrhönen S; Turpeenniemi-Hujanen T; Asola R; Leinonen M; Hahka-Kemppinen M; Kellokumpu-Lehtinen P
    Ann Oncol; 2010 May; 21(5):968-73. PubMed ID: 19819914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
    Kawaguchi H; Masuda N; Nakayama T; Aogi K; Anan K; Ito Y; Ohtani S; Sato N; Saji S; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita H; Yamashita T; Yamamoto Y; Yotsumoto D; Toi M; Ohno S
    Breast Cancer; 2020 May; 27(3):389-398. PubMed ID: 31811519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
    Baselga J; Gómez P; Greil R; Braga S; Climent MA; Wardley AM; Kaufman B; Stemmer SM; Pêgo A; Chan A; Goeminne JC; Graas MP; Kennedy MJ; Ciruelos Gil EM; Schneeweiss A; Zubel A; Groos J; Melezínková H; Awada A
    J Clin Oncol; 2013 Jul; 31(20):2586-92. PubMed ID: 23733761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
    Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
    Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.